UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No.1 and Amendment No.3)*
QUESTCOR PHARMACEUTICALS INC.
- ------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
- ------------------------------------------------------------------------------
(Title of Class of Securities)
232808105
- ------------------------------------------------------------------------------
(CUSIP Number)
Joseph J. Giunta, Esq.
- ------------------------------------------------------------------------------
Skadden, Arps, Slate, Meagher & Flom LLP
300 South Grand Avenue
Los Angeles, CA 90071
(213) 687-5000
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
January 16, 2003
- ------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is filing
this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-(1)(g),
check the following box [ ].
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
SCHEDULE 13D
- ------------------------------------------------------------------------------
CUSIP No. 232808105
- ------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Claudio Cavazza
- ------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)
- ------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------
4 SOURCE OF FUNDS
PF, AF
- ------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e)
- ------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Italy
- ------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 2,656,781
SHARES ---------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 10,698,712
EACH ---------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON WITH 2,656,781
---------------------------------------------
10 SHARED DISPOSITIVE POWER
10,698,712
- ------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
13,355,493
- ------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES
- ------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
32.11%
- ------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
IN
- ------------------------------------------------------------------------------
SCHEDULE 13D
- ------------------------------------------------------------------------------
CUSIP No. 232808105
- ------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Paolo Cavazza
- ------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)
- ------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------
4 SOURCE OF FUNDS
PF, AF
- ------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e)
- ------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Italy
- ------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 2,656,782
SHARES ---------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 11,147,812
EACH ---------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON WITH 2,656,782
---------------------------------------------
10 SHARED DISPOSITIVE POWER
11,147,812
- ------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
13,804,594
- ------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES
- ------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
33.19%
- ------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
IN
- ------------------------------------------------------------------------------
SCHEDULE 13D
- ------------------------------------------------------------------------------
CUSIP No. 232808105
- ------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Sigma-Tau Finanziaria SpA
- ------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)
- ------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------
4 SOURCE OF FUNDS
AF
- ------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e)
- ------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Italy
- ------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES ----------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 10,698,712
EACH
REPORTING ----------------------------------------------
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
----------------------------------------------
10 SHARED DISPOSITIVE POWER
10,698,712
- ------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10,698,712
- ------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES
- ------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
26.29%
- ------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
CO
- ------------------------------------------------------------------------------
SCHEDULE 13D
- ------------------------------------------------------------------------------
CUSIP No. 232808105
- ------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Sigma Tau International S.A.
- ------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)
- ------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
- ------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e)
- ------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg
- ------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES ----------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 10,698,712
EACH
REPORTING ----------------------------------------------
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
----------------------------------------------
10 SHARED DISPOSITIVE POWER
10,698,712
- ------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10,698,712
- ------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES
- ------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
26.29%
- ------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
CO
- ------------------------------------------------------------------------------
SCHEDULE 13D
- ------------------------------------------------------------------------------
CUSIP No. 232808105
- ------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Defiante Farmaceutica L.D.A.
- ------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)
- ------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
- ------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e)
- ------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Portugal
- ------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES ----------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 2,025,315
EACH
REPORTING ----------------------------------------------
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
----------------------------------------------
10 SHARED DISPOSITIVE POWER
2,025,315
- ------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,025,315
- ------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES
- ------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.98%
- ------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
CO
- ------------------------------------------------------------------------------
Amendment No. 1 and
Amendment No. 3 to
Statement on Schedule 13D
This Amendment No. 1 (the "Amendment No. 1") amends the Statement
on Schedule 13D filed with the Securities and Exchange Commission ("SEC") on
March 25, 2002 (the "Sigma/Defiante Schedule 13D"). This Amendment No. 3 (the
"Amendment No. 3," and together with the Amendment No. 1, this "Statement")
amends the Statement on Schedule 13D, filed with the SEC on August 7, 2001
(the "Cavazza/Sigma Schedule 13D," and together with the Sigma/Defiante
Schedule 13D, the "Schedule 13Ds"), as amended.
Item 1. Security and Issuer.
-------------------
Item 1 of the Schedule 13Ds are hereby amended as follows:
The class of equity securities to which this Statement relates is
the common stock, no par value (the "Common Stock"), of Questcor
Pharmaceuticals Inc., a California corporation ("Questcor"). The principal
executive offices of Questcor are located at 3620 Whipple Road, Union City,
California, 94587.
Item 2. Identity and Background.
-----------------------
Item 2 of the Schedule 13Ds are hereby amended as follows:
This Amendment No. 1 is being filed on behalf of Sigma-Tau
Finanziaria SpA, an Italian corporation ("Sigma Tau") and Defiante
Farmaceutica L.D.A., a Portuguese corporation ("Defiante") (formerly known as
Defiante Farmaceutica Unipessoal L.D.A.), and this Amendment No. 3 is being
filed on behalf of Sigma Tau International S.A., a Luxembourg corporation
("Sigma Tau International") (formerly known as Sigma-Tau Finance Holding
S.A.), Mr. Claudio Cavazza ("Mr. C. Cavazza") and Mr. Paolo Cavazza ("Mr. P.
Cavazza," and together with Mr. C. Cavazza, Sigma Tau International, Defiante
and Sigma Tau, the "Reporting Persons"). Sigma Tau owns 100% of the capital
stock of Sigma Tau International and 58% of the capital stock of Defiante.
Sigma Tau International owns 42% of the capital stock of Defiante, which it
obtained pursuant to an intercompany transfer during fall of 2002. Mr. C.
Cavazza owns, directly and indirecty, 60% of Sigma Tau and Mr. P. Cavazza
owns, directly and indirectly, 40% of Sigma Tau.
The business address of Mr. C. Cavazza and Sigma Tau is Via
Sudafrica, 20, 00144 Rome, Italy. Mr. C. Cavazza's principal occupation is as
an entrepreneur in the pharmaceutical business. The principal business of
Sigma Tau is as a parent holding company whose principal assets consists of
the common stock of its subsidiaries which form a fully integrated
pharmaceutical company operating in Europe, the United States and Africa.
The business address of Mr. P. Cavazza is Via Tesserete, 10,
Lugano, Switzerland. Mr. P. Cavazza's principal occupation is as an
entrepreneur in the pharmaceutical business.
The business address of Sigma Tau International is 19-21 Boulevard
du Prince Henri, L-1724, Luxembourg. Sigma Tau International is a holding
company whose principal assets consist of the common stock of various entities
mainly in the pharmaceutical industry.
The business address of Defiante is Rua dos Ferreiros, 260
Funchal-Madeira, Portogallo 9000-082. Defiante is a commercial pharmaceutical
company.
The name, address, principal occupation or employment and
citizenship of each of the executive officers and directors of Sigma-Tau,
Sigma Tau International and Defiante are set forth in Schedule A hereto.
Neither the Reporting Persons nor any of the persons listed on Schedule A has
been, during the last five years, (a) convicted in a criminal proceeding
(excluding traffic violations or similar misdemeanors) or (b) a party to a
civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result of such proceeding was or is subject to a
judgment, decree or final order enjoining future violations of, or prohibiting
or mandating activities subject to, federal or state securities laws or
finding any violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration.
-------------------------------------------------
Item 3 of the Schedule 13Ds are hereby amended to add the following:
From March 14, 2002 through the date hereof, Sigma Tau
International used its working capital to acquire ownership of the following
shares of Common Stock:
- ------------------------------------- ------------ -----------------------------
Date of Purchase Amount Price per share
- ------------------------------------- ------------ -----------------------------
3/14/02 5,000 $1.6374
- ------------------------------------- ------------ -----------------------------
3/15/02 5,000 $1.7450
- ------------------------------------- ------------ -----------------------------
3/18/02 5,000 $1.8642
- ------------------------------------- ------------ -----------------------------
3/19/02 10,000 $1.8492
- ------------------------------------- ------------ -----------------------------
3/20/02 10,000 $1.8156
- ------------------------------------- ------------ -----------------------------
3/21/02 10,000 $1.8200
- ------------------------------------- ------------ -----------------------------
3/22/02 10,000 $1.8230
- ------------------------------------- ------------ -----------------------------
3/25/02 10,000 $1.7912
- ------------------------------------- ------------ -----------------------------
3/26/02 10,000 $1.8455
- ------------------------------------- ------------ -----------------------------
3/27/02 10,000 $1.8393
- ------------------------------------- ------------ -----------------------------
3/28/02 10,000 $1.9439
- ------------------------------------- ------------ -----------------------------
4/01/02 10,000 $1.9358
- ------------------------------------ ------------ -----------------------------
4/02/02 10,000 $1.9650
- ------------------------------------- ------------ -----------------------------
4/03/02 10,000 $1.9547
- ------------------------------------- ------------ -----------------------------
4/04/02 10,000 $1.9462
- ------------------------------------ ------------ -----------------------------
4/05/02 10,000 $2.0039
- ------------------------------------- ------------ -----------------------------
4/08/02 10,000 $1.9865
- ------------------------------------- ------------ -----------------------------
4/09/02 10,000 $2.0354
- ------------------------------------- ------------ -----------------------------
4/10/02 10,000 $1.9338
- ------------------------------------- ------------ -----------------------------
4/11/02 10,000 $1.9385
- ------------------------------------- ------------ -----------------------------
4/12/02 10,000 $1.9698
- ------------------------------------- ------------ -----------------------------
4/15/02 10,000 $1.9616
- ------------------------------------- ------------ -----------------------------
4/16/02 10,000 $1.9249
- ------------------------------------- ------------ -----------------------------
5/15/02 5,000 $1.7482
- ------------------------------------- ------------ -----------------------------
5/16/02 5,000 $1.7626
- ------------------------------------- ------------ -----------------------------
5/17/02 5,000 $1.7158
- ------------------------------------- ------------ -----------------------------
5/20/02 5,000 $1.6418
- ------------------------------------- ------------ -----------------------------
5/21/02 10,000 $1.7000
- ------------------------------------- ------------ -----------------------------
5/21/02 10,000 $1.6000
- ------------------------------------- ------------ -----------------------------
5/22/02 10,000 $1.5980
- ------------------------------------- ------------ -----------------------------
5/23/02 10,000 $1.6500
- ------------------------------------- ------------ -----------------------------
5/24/02 10,000 $1.6500
- ------------------------------------- ------------ -----------------------------
5/28/02 10,000 $1.6500
- ------------------------------------- ------------ -----------------------------
5/29/02 10,000 $1.6600
- ------------------------------------- ------------ -----------------------------
5/29/02 10,000 $1.6100
- ------------------------------------- ------------ -----------------------------
5/30/02 8,200 $1.6100
- ------------------------------------- ------------ -----------------------------
5/31/02 10,000 $1.6600
- ------------------------------------- ------------ -----------------------------
6/03/02 10,000 $1.660
- ------------------------------------- ------------ -----------------------------
6/04/02 10,000 $1.680
- ------------------------------------- ------------ -----------------------------
6/04/02 10,000 $1.630
- ------------------------------------- ------------ -----------------------------
6/06/02 10,000 $1.550
- ------------------------------------- ------------ -----------------------------
6/07/02 20,000 $1.500
- ------------------------------------- ------------ -----------------------------
6/11/02 10,000 $1.450
- ------------------------------------- ------------ -----------------------------
6/12/02 10,000 $1.400
- ------------------------------------- ------------ -----------------------------
6/24/02 10,000 $1.400
- ------------------------------------- ------------ -----------------------------
6/26/02 10,000 $1.300
- ------------------------------------- ------------ -----------------------------
7/03/02 10,000 $1.2000
- ------------------------------------- ------------ -----------------------------
7/10/02 10,000 $1.0000
- ------------------------------------- ------------ -----------------------------
7/10/02 10,000 $1.1000
- ------------------------------------- ------------ -----------------------------
7/18/02 5,000 $1.1958
- ------------------------------------- ------------ -----------------------------
7/19/02 5,000 $1.1984
- ------------------------------------- ------------ -----------------------------
7/22/02 5,000 $1.1068
- ------------------------------------- ------------ -----------------------------
7/22/02 10,000 $1.1000
- ------------------------------------- ------------ -----------------------------
8/22/02 5,000 $1.1000
- ------------------------------------- ------------ -----------------------------
8/23/02 5,000 $1.1000
- ------------------------------------- ------------ -----------------------------
8/27/02 2,600 $1.1000
- ------------------------------------- ------------ -----------------------------
In addition, from March 1, 2002 through the date hereof, Mr. P.
Cavazza obtained beneficial ownership of the following shares of Common Stock
through his ownership of Aptafin S.p.A., which acquired the shares with its
working capital:
- ------------------------------------- ------------ -----------------------------
Date of Purchase Amount Price per share
- ------------------------------------- ------------ -----------------------------
3/01/02 10,000 $1.600
- ------------------------------------- ------------ -----------------------------
3/01/02 4,800 $1.550
- ------------------------------------- ------------ -----------------------------
3/05/02 5,200 $1.550
- ------------------------------------- ------------ -----------------------------
3/05/02 10,000 $1.450
- ------------------------------------- ------------ -----------------------------
3/07/02 9,500 $1.530
- ------------------------------------- ------------ -----------------------------
3/07/02 500 $1.460
- ------------------------------------- ------------ -----------------------------
3/13/02 9,500 $1.500
- ------------------------------------- ------------ -----------------------------
3/13/02 500 $1.480
- ------------------------------------- ------------ -----------------------------
3/18/02 6,400 $1.860
- ------------------------------------- ------------ -----------------------------
3/18/02 3,600 $1.850
- ------------------------------------- ------------ -----------------------------
3/22/02 7,500 $1.830
- ------------------------------------- ------------ -----------------------------
3/22/02 2,500 $1.810
- ------------------------------------- ------------ -----------------------------
5/16/02 6,500 $1.7000
- ------------------------------------- ------------ -----------------------------
5/17/02 3,500 $1.7000
- ------------------------------------- ------------ -----------------------------
5/20/02 10,000 $1.6500
- ------------------------------------- ------------ -----------------------------
5/21/02 10,000 $1.6000
- ------------------------------------- ------------ -----------------------------
8/26/02 5,000 $1.150
- ------------------------------------- ------------ -----------------------------
Sigma Tau International obtained beneficial ownership of 2,025,315
shares of Common Stock pursuant to an intercompany transfer of 42% of Defiante
from Sigma Tau during fall of 2002.
Item 4. Purpose of the Transaction.
--------------------------
Item 4 of the Schedule 13Ds are hereby amended as follows:
The Reporting Persons originally acquired the shares reported
herein to gain an equity investment interest in Questcor. The Reporting
Persons evaluate on an ongoing basis Questcor's financial condition, business
operations and prospects. To enable them to better make such evaluations, Mr.
Mauro Bove ("Mr. Bove"), on behalf of the Reporting Persons, had a telephonic
conversation on January 16, 2003 with Mr. Charles Casamento ("Mr. Casamento"),
Chairman, President and CEO of Questcor, requesting representation on the
Questcor Board of Directors (the "Board"). Specifically, Mr. Bove requested an
increase in the number of directors of Questcor by two, such directors to be
nominated by the Reporting Persons and elected by the Board as soon as
possible (the "Request"). Mr. Casamento informed Mr. Bove that he will discuss
the Request with the Board during the next meeting of the Board to be held on
January 24, 2003. Upon conclusion of the meeting, Mr. Casamento will advise
Mr. Bove of the Board's decision.
Except as set forth in this Item 4, the Reporting Persons have no
present plans or proposals that relate to or that would result in any of the
actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the
Act.
Item 5. Interest in Securities of Questcor.
----------------------------------
Item 5 of the Schedule 13Ds are hereby amended as follows:
(a) Percentage interest calculations for the Reporting Persons are
based upon Questcor having 38,672,583 shares of Common Stock outstanding as of
November 7, 2002, as reported by the Issuer in the Issuer's Form 10-Q for the
quarterly period ended September 30, 2002 filed with the SEC on November 12,
2002.
Mr. C. Cavazza
--------------
Pursuant to Rule 13d-3 of the Act, Mr. C. Cavazza may be
deemed to be the beneficial owner of 13,355,493 shares of Common Stock, which
constitutes approximately 32.11% of the shares of Common Stock outstanding.
Mr. P. Cavazza
--------------
Pursuant to Rule 13d-3 of the Act, Mr. P. Cavazza may be deemed to
be the beneficial owner of 13,804,594 shares of Common Stock, which
constitutes approximately 33.19% of the shares of Common Stock outstanding.
Sigma Tau International
-----------------------
Pursuant to Rule 13d-3 of the Act, Sigma Tau International may be
deemed to be the beneficial owner of 10,698,712 shares of Common Stock, which
constitutes approximately 26.29% of the shares of Common Stock outstanding.
Sigma Tau
---------
Pursuant to Rule 13d-3 of the Act, Sigma Tau may be deemed to be
the beneficial owner of 10,698,712 shares of Common Stock, which constitutes
approximately 26.29% of the shares of Common Stock outstanding.
Defiante
--------
Pursuant to Rule 13d-3 of the Act, Defiante may be deemed to be
the beneficial owner of 2,025,315 shares of Common Stock, which constitutes
approximately 4.98% of the shares of Common Stock outstanding.
Except as set forth above, none of the Reporting Persons nor any
of the persons listed on Schedule A beneficially owns any other shares of
Common Stock.
(b) Mr. C. Cavazza
--------------
The number of shares of Common Stock as to which Mr. C. Cavazza
has the sole power to vote or direct the vote is 2,656,781. The number of
shares of Common Stock as to which Mr. C. Cavazza shares the power to vote or
direct the vote is 10,698,712. The number of shares of Common Stock as to
which Mr. C. Cavazza has the sole power to dispose or direct the disposition
is 2,656,781. The number of shares of Common Stock as to which Mr. C. Cavazza
shares the power to dispose or direct the disposition is 10,698,712.
Mr. P. Cavazza
--------------
The number of shares of Common Stock as to which Mr. P. Cavazza
has the sole power to vote or direct the vote is 2,656,782. The number of
shares of Common Stock as to which Mr. P. Cavazza shares the power to vote or
direct the vote is 11,147,812. The number of shares of Common Stock as to
which Mr. P. Cavazza has the sole power to dispose or direct the disposition
is 2,656,782. The number of shares of Common Stock as to which Mr. P. Cavazza
shares the power to dispose or direct the disposition is 11,147,812.
Sigma Tau International
-----------------------
The number of shares of Common Stock as to which Sigma Tau
International has the sole power to vote or direct the vote is zero. The
number of shares of Common Stock as to which Sigma Tau International shares
the power to vote or direct the vote is 10,698,712. The number of shares of
Common Stock as to which Sigma Tau International has the sole power to dispose
or direct the disposition is zero. The number of shares of Common Stock as to
which Sigma Tau International shares the power to dispose or direct the
disposition is 10,698,712.
Sigma Tau
---------
The number of shares of Common Stock as to which Sigma Tau has the
sole power to vote or direct the vote is zero. The number of shares of Common
Stock as to which Sigma Tau shares the power to vote or direct the vote is
10,698,712. The number of shares of Common Stock as to which Sigma Tau has the
sole power to dispose or direct the disposition is zero. The number of shares
of Common Stock as to which Sigma Tau shares the power to dispose or direct
the disposition is 10,698,712.
Defiante
--------
The number of shares of Common Stock as to which Defiante has the
sole power to vote or direct the vote is zero. The number of shares of Common
Stock as to which Defiante shares the power to vote or direct the vote is
2,025,315. The number of shares of Common Stock as to which Defiante has the
sole power to dispose or direct the disposition is zero. The number of shares
of Common Stock as to which Defiante shares the power to dispose or direct the
disposition is 2,025,315.
Item 6. Contracts, Arrangements, Understandings or
Relationships with Respect to Securities
of Questcor.
------------------------------------------
Except as previously disclosed in the Schedule 13Ds or set forth
in this Statement, to the best knowledge of the Reporting Persons there are no
other contracts, arrangements, understandings or relationships (legal or
otherwise) among the persons named in Item 2 and between such persons and any
person with respect to any securities of Questcor, including but not limited
to, transfer or voting of any of the securities of Questcor, finders fees,
joint ventures, loan or options arrangements, puts or calls, guarantees of
profits, division of profits or loss, or the giving or withholding of proxies,
or a pledge or contingency the occurrence of which would give another person
voting power over the securities of Questcor.
Item 7. Material to be Filed as Exhibits.
--------------------------------
EXHIBIT 1 - Joint Filing Agreement dated January 17, 2003 by and
between the Reporting Persons.
Signatures
----------
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement with
respect to Claudio Cavazza is true, complete and correct.
Dated: January 17, 2003
CLAUDIO CAVAZZA
By: /s/ CLAUDIO CAVAZZA
---------------------------
Name: Claudio Cavazza
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement with
respect to Paolo Cavazza is true, complete and correct.
Dated: January 17, 2003
PAOLO CAVAZZA
By: /s/ PAOLO CAVAZZA
---------------------------
Name: Paolo Cavazza
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement with
respect to Sigma-Tau Finanziaria SpA is true, complete and correct.
Dated: January 17, 2003
SIGMA-TAU FINANZIARIA SPA
By: /s/ MARIO ARTALI
---------------------------
Name: Mario Artali
Title: Managing Director
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement with
respect to Sigma-Tau International S.A. is true, complete and correct.
Dated: January 17, 2003
SIGMA-TAU INTERNATIONAL S.A.
By: /s/ ANTONIO NICOLAI
---------------------------
Name: Antonio Nicolai
Title: Director
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement with
respect to Defiante Farmaceutica L.D.A. is true, complete and correct.
Dated: January 17, 2003
DEFIANTE FARMACEUTICA L.D.A.
By: /s/ RAFFAELE SANGUIGNI
---------------------------
Name: Raffaele Sanguigni
Title: Director
The original statement shall be signed by each person on whose
behalf the statement is filed or his authorized representative. If the
statement is signed on behalf of a person by his authorized representative
(other than an executive officer or general partner of the filing person),
evidence of the representative's authority to sign on behalf of such person
shall be filed with the statement: provided, however, that a power of attorney
for this purpose which is already on file with the Commission may be
incorporated by reference. The name and any title of each person who signs the
statement shall be typed or printed beneath his signature.
Attention: Intentional misstatements or omissions of fact constitute Federal
criminal violations (See 18 U.S.C. 1001)
Schedule A
EXECUTIVE OFFICERS AND DIRECTORS
--------------------------------
Sigma-Tau Finanziaria SpA
-------------------------
NAME ADDRESS TITLE CITIZENSHIP
---- ------- ----- -----------
Claudio Cavazza via Sudafrica,20, President Italian
Rome Italy-00144
Mario Artali via Sudafrica,20, Managing Italian
Rome Italy-00144 Director
Antonio Nicolai via Sudafrica,20, Director Italian
Rome Italy-00144
Vittorio Ripa di Meana via Sudafrica,20, Director Italian
Rome Italy-00144
Mauro Bove via Sudafrica,20, Director Italian
Rome Italy-00144
Piero Belletti via Sudafrica,20, Director Italian
Rome Italy-00144
Schedule A
----------
EXECUTIVE OFFICERS AND DIRECTORS
Sigma-Tau International S.A.
----------------------------
NAME ADDRESS TITLE CITIZENSHIP
---- ------- ----- -----------
Mario Artali via Sudafrica,20, President Italian
Rome Italy-00144
Jean-Marc Leonard 19-21 Boulevard Director Luxembourg
du Prince Henri
L-1724 Luxembourg
Luca Checchinato 19-21 Boulevard du Director Luxembourg
Prince Henri
L-1724 Luxembourg
Antonio Nicolai via Sudafrica,20, Director Italian
Rome Italy-00144
Mauro Bove via Sudafrica,20, Director Italian
Rome Italy-00144
Gustave Stoffel Avenue Pasteur,6 Director Luxembourg
LP-2310 Luxembourg
Maryse Santini 19-21 Boulevard du Director Luxembourg
Prnce Henri
L-1724 Luxembourg
Schedule A
----------
EXECUTIVE OFFICERS AND DIRECTORS
--------------------------------
Defiante Farmaceutica L.D.A.
----------------------------
NAME ADDRESS TITLE CITIZENSHIP
---- ------- ----- -----------
Antonio Nicolai via Sudafrica,20, Director Italian
Rome Italy-00144
Raffaele Sanguigni Rua dos Ferreiros, Director Italian
260 - Funchal -
Madeira - Portugal 9000-082
Antonio Guilherme Rua dos Ferreiros, Director Portuguese
Rodrigues Frutuoso de Melo 260 - Funchal -
Madeira - Portugal 9000-082
Pedro Moreira da Rua dos Ferreiros, Director Portuguese
Cruz Quintas 260 - Funchal -
Madeira - Portugal 9000-082
Carla Emanuel Arruda Rua dos Ferreiros, Director Portuguese
Jardim Fernandes 260 - Funchal -
Madeira - Portugal 9000-082
EXHIBIT 1
JOINT FILING AGREEMENT
The undersigned hereby agree that the statement on the Schedule
13D with respect to the Common Stock of Questcor Pharmaceuticals, Inc. dated
as of January 17, 2003 is, and any amendments thereto signed by each of the
undersigned shall be, filed on behalf of each of us pursuant to and in
accordance with the provisions of Rule 13d-1(f) under the Securities Exchange
Act of 1934.
Dated: January 17, 2003 CLAUDIO CAVAZZA
By: /s/ CLAUDIO CAVAZZA
----------------------------
Name: Claudio Cavazza
Dated: January 17, 2003 PAOLO CAVAZZA
By: /s/ PAOLO CAVAZZA
----------------------------
Name: Paolo Cavazza
Dated: January 17, 2003 SIGMA TAU FINANZIARIA SPA
By: /s/ MARIO ARTALI
----------------------------
Name: Mario Artali
Title: Managing Director
Dated: January 17, 2003 SIGMA TAU International S.A.
By: /s/ ANTONIO NICOLAI
----------------------------
Name: Antonio Nicolai
Title: Director
Dated: January 17, 2003 DEFIANTE FARMACEUTICA L.D.A.
By: /s/ RAFFAELE SANGUIGNI
----------------------------
Name: Raffaele Sanguigni
Title: Director